Dr. Padmanee Sharma, and oncologist at The University of Texas M.D Anderson Cancer Center, in Houston, discusses her recent success in boosting the benefit of a checkpoint inhibitor in metastatic renal cancer with the addition of the VEGF-inhibitor bevacizumab. She goes on to explain why the immunotherapy field is moving quickly to combination strategies.
MAY 16, 2017